A kind of preparation method of ivermectin

Through the method of combining macroporous adsorption resin and liquid chromatography column, the problem of complex preparation process and difficult to meet the purity standards is solved, and high-purity and high yield ivermectin preparation is achieved, which is suitable for industrial production. Improves environmental safety.

CN115873050BActive Publication Date: 2024-11-08ZHEJIANG HUIDA BIOTECHNOLOGY CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202111141676.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-09-28
Publication Date
2024-11-08
Estimated Expiration
2041-09-28

AI Technical Summary

Technical Problem

The existing ivermectin preparation methods are complex in technology, high in production costs, and difficult to meet the requirements of medicinal purity, especially in industrial production, there are problems of environmental pollution and complex operation.

Method used

The crude ivermectin product is enriched with macroporous adsorption resin, and the high-purity ivermectin is refined by liquid chromatography column and precipitated through crystallization. The process is simple, the solvent used is safe and environmentally friendly, and is suitable for large-scale production.

Benefits of technology

It achieves high purity (over 98%) and high yield (over 50%) of ivermectin, effectively controls impurity content, simplifies the process flow, reduces production costs, and improves environmental safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115873050B_ABST
    Figure CN115873050B_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of ivermectin, comprising the following steps: 1) enriching ivermectin crude product with macroporous resin; 2) refining ivermectin crude product with a preparative liquid chromatography column; 3) obtaining high-purity ivermectin refined powder by crystallization. The preparation method of the invention has a yield of more than 50%, an ivermectin purity of more than 98%, various impurities are effectively controlled, and high-purity ivermectin can be produced on a large scale.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention specifically relates to a method for preparing ivermectin, and belongs to the field of preparation of biological drugs. Background Art

[0002] Ivermectin is a mixture of two homologues of natural avermectin, 22,23-dihydroavermectin B1a and dihydroavermectin B1b, with a ratio of 80:20. Since its launch in 1981, ivermectin has been used in agriculture, veterinary medicine and aquaculture, and is effective against a variety of nematodes, insects and mites at low doses. In addition, it is also very effective against most common intestinal worms (except tapeworms), can be administered orally, topically or parenterally, and has no signs of cross-resistance with other commonly used antiparasitic compounds. In 1987, ivermectin began to be used to treat a variety of parasitic infections in humans, including head lice, scabies, river blindness (onchocerciasis), strongyloidiasis, whipworm disease and lymphatic filariasis.

[0003]

[0004] So far, there are two main preparation methods for ivermectin. One is to obtain ivermectin by hydrogenation selective reduction of avermectin B1 by chemical method. This chemical method requires separation and purification of avermectin B1 from the fermentation broth of Streptomyces avermitilis, hydrogenation reduction of avermectin to ivermectin, and subsequent separation and purification. This preparation method is complex and has high production cost. The other is to directly separate and purify ivermectin from the fermentation broth. The composition of ivermectin fermentation broth is very complex, especially there are many impurities similar to the structure of ivermectin, and medicinal ivermectin has higher limit requirements for related impurities. For example, the United States Pharmacopoeia (USP) requires the control of known impurities avermectin B1a ≤ 0.7%, 8a-oxo-H2B1a ≤ 1%, the sum of H4B1a isomers and Δ2,3H2B1a ≤ 2.5%, unknown single impurities ≤ 0.5%, the total of unknown impurities ≤ 1%; total impurities ≤ 4%. In summary, the direct preparation process of ivermectin has brought great challenges. For example, U.S. Patent No. 6265571 discloses a method for separating and purifying ivermectin from a fermentation broth. The specific purification step includes gradient elution using a reverse phase flash chromatography system. Although the method can provide a high-purity standard product of ivermectin with a purity of 98%, the technology is only suitable for small-scale preparation in the laboratory, which is not conducive to industrialization. U.S. Patent No. 4429042A discloses a method for separating and purifying ivermectin from a fermentation broth, which specifically includes using silica gel, alumina, dextran coagulation and other fillers and corresponding different types of mobile phases for chromatographic separation to obtain the required components. The process is complicated to operate, requires a large number of solvents, and causes greater environmental pollution, which is also not conducive to industrial production. Summary of the invention

[0005] The invention provides a preparation process for directly obtaining high-purity ivermectin from ivermectin fermentation broth. The preparation method has simple process, high ivermectin yield and high purity, safe and environmentally friendly solvent, and can be mass-produced.

[0006] Specifically, the preparation method of ivermectin adopted in the present invention comprises the following steps:

[0007] a) separating the ivermectin fermentation liquid from solid, extracting the slag with an organic solvent I, loading the extract onto a macroporous adsorption resin, eluting with an organic solvent I-water solution, collecting and concentrating the eluate I, adding an extractant I to the concentrate for extraction, and concentrating the extracted organic phase to a paste;

[0008] b) dissolving the paste obtained in step a) with an organic solvent II to prepare a column liquid, feeding the obtained column liquid into a preparative liquid chromatography column, using an organic solvent II-aqueous solution as a mobile phase, performing chromatography detection, and collecting an ivermectin qualified component eluate II;

[0009] c) After the eluate II obtained in step b) is concentrated until a white solid is precipitated, an extractant II is added for extraction, and the extracted organic phase is concentrated to a paste, and then an organic solvent III is added for dissolution, and n-hexane is added dropwise to the obtained pre-crystallization liquid to precipitate crystals, which are filtered and dried to obtain the finished ivermectin.

[0010] Preferably, the macroporous adsorption resin in step a) is selected from polystyrene resins, preferably LX-T28, LX-30, LX-60, LX-T83, LX-98, PAD900, SP-207, further preferably LX-30, PAD900 or SP-207, more preferably LX-30.

[0011] Preferably, the filler used to prepare the liquid phase column in step b) is C18 filler, preferably Nano C18 filler, Huapu C18 filler, Kromasil C18 filler, and more preferably Kromasil C18 filler.

[0012] Preferably, in step c), the organic solvent III is preferably ethyl acetate or dichloromethane, more preferably ethyl acetate; the mass volume ratio of the paste to the organic solvent III is 10-30:100 g / mL, preferably 25:100 g / mL.

[0013] Preferably, the organic solvent II in step b) is preferably methanol or acetonitrile, more preferably methanol; the mass volume ratio of the paste to the organic solvent II is 2-5:100 g / mL.

[0014] Preferably, the ratio of organic solvent II to water in the mobile phase of step b) is 80% to 90%, preferably 85%; the flow rate is 50 mL / min to 70 mL / min, preferably 70 ml / min.

[0015] Preferably, the extractant I and the extractant II in steps a) and c) are selected from chloroform, dichloromethane, ethyl acetate, and hexane, preferably dichloromethane and ethyl acetate, and more preferably ethyl acetate; the mass volume ratio of the paste I to the extractant I is 0.6-0.8:100 g / mL, and the mass volume ratio of the paste II to the extractant II is 1.2-1.6:100 g / mL.

[0016] Preferably, the particle size of the macroporous adsorption resin in step a) is 0.35 mm to 0.45 mm, and the pore size is The shape is spherical.

[0017] Preferably, in step a), the organic solvent I is preferably ethanol, acetone, methanol, preferably ethanol; the volume ratio of the organic solvent I to the aqueous solution is 70% to 90%.

[0018] Preferably, the filler particle size of the liquid phase prepared in step b) is 8 μm and the pore size is

[0019] The ivermectin preparation method of the present invention enriches ivermectin crude product by macroporous resin, obtains refined ivermectin by preparing liquid chromatography column, and then obtains high-purity ivermectin fine powder by crystallization. The overall preparation process is simple, the solvent used in the process is safe and environmentally friendly, the ivermectin yield reaches more than 50%, the purity of the obtained ivermectin can reach more than 98%, various impurities are effectively controlled, and high-purity ivermectin can be directly produced from ivermectin fermentation liquid on a large scale. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Liquid phase spectrum of ivermectin fermentation broth

[0021] Figure 2 Spectrum of ivermectin product prepared on a large scale DETAILED DESCRIPTION

[0022] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0023] Unless otherwise specified, the materials and reagents used in the following examples are all common commercial products and can be purchased on the market; among them, Nano-C18 filler was purchased from Suzhou Nano-C18 Company, Huapu C18 filler was purchased from Huapu Technology Company, and Kromasil C18 filler was purchased from Akzo Nobel.

[0024] The fermentation strain used in the embodiment of the present invention is a gram-positive bacterium Streptomyces avermectinius or a mutant of Streptomyces avermectinius. Mutants producing ivermectin obtained by X-ray irradiation, ultraviolet irradiation, nitrogen mustard or genetic engineering are also included in the scope of the present invention, such as the ivermectin-producing Streptomyces avermitilis ATCC31267 or ATCC 31272 strain described in U.S. Pat. No. 4,429,042A. The fermentation conditions are similar to those of general Streptomyces, i.e., fermentation at pH 5.0-9.0 (preferably pH 7.0-7.5) and 20-45° C. (preferably 25-40° C.) in a medium containing a carbon source, a nitrogen source and trace elements.

[0025] The present invention will be further described below by way of examples, which are not intended to further limit the present invention. It should be understood by those skilled in the art that equivalent replacements or corresponding improvements made to the present invention still fall within the scope of protection of the present invention.

[0026] Example 1

[0027] The fermentation liquid obtained by fermenting the ivermectin-producing strain is separated into a filter residue by a plate-and-frame filter device, and then ethanol is used for extraction to obtain an ethanol extract; 1L of the ethanol extract containing ivermectin (containing 2.3 grams of ivermectin) is taken and loaded onto an LX-30 resin column. After loading, water washing is started, and then eluted with a 70% ethanol-water (V:V) solution. The obtained eluate begins to be concentrated until there is no droplet, 800mL of ethyl acetate is added for extraction, and after stirring and standing for separation, an ethyl acetate phase is obtained, and the ethyl acetate phase is then concentrated to a paste, and 50ml of methanol is added to dissolve to obtain a preparative column liquid, and the liquid phase detection concentration is 36.8mg / mL. The above-mentioned dissolved liquid is loaded into a DAC50 preparative liquid chromatograph with Kromasil C18 filler, and the mobile phase is 85% methanol-water solution (V:V), the ultraviolet detection wavelength is 254nm, and the flow rate is 70mL / min. The effective components were collected and then combined to control the known impurities Avermectin B1a ≤ 0.7%, 8a-oxo-H2B1a ≤ 1%, the sum of H4B1a isomers and Δ2,3H2B1a ≤ 2.5%; unknown single impurities ≤ 0.5%. The chromatographic purity of the main peak of ivermectin is ≥98%; after the qualified components are concentrated again until a white solid is precipitated, 150 mL of ethyl acetate is added for extraction, and after stirring and standing for liquid separation, an ethyl acetate phase is obtained, and the ethyl acetate phase is concentrated to a paste, 14 mL of ethyl acetate is added according to a pre-crystallization liquid concentration of 10:100 g / mL, and n-hexane is added dropwise until a solid is precipitated, and then filtered and dried to obtain 1.4 grams of a finished product that meets the USP quality standard (known impurities avermectin B1a=0%, 8a-oxo-H2B1a=0.11%, the sum of H4B1a isomers and Δ2,3H2B1a=0%; unknown single impurity=0.34%. The chromatographic purity of the main peak of ivermectin=98.33%;), and the total yield is 60%.

[0028] Example 2

[0029] The fermentation liquid obtained by fermentation of ivermectin-producing strains is separated into filter residues by a plate-and-frame filter device, and then extracted with methanol to obtain an ethanol extract; 1.5L of methanol extract containing ivermectin (containing 3.7 grams of ivermectin) is taken and loaded onto a PAD900 resin column. After loading, water washing is started, and then eluted with an 80% methanol-water (V:V) solution. The obtained eluate begins to be concentrated until there is no droplet, 1.3L of dichloromethane is added for extraction, and after stirring and standing for liquid separation, a dichloromethane phase is obtained, and the dichloromethane phase is then concentrated to a paste, and 75ml of methanol is added to dissolve to prepare the column liquid, and the liquid phase detection concentration is 39.4mg / mL. The above-mentioned dissolved liquid is loaded into a DAC50 preparative liquid chromatograph with Huapu C18 filler, and the mobile phase is 70% methanol-water solution, the ultraviolet detection wavelength is 254nm, and the flow rate is 70mL / min. Collect the effective components, and then combine them to control the known impurities avermectin B1a ≤ 0.7%, 8a-oxo-H2B1a ≤ 1%, the sum of H4B1a isomers and Δ2,3H2B1a ≤ 2.5%; unknown single impurities ≤ 0.5%, and the chromatographic purity of the main peak of ivermectin ≥ 98%; concentrate the qualified components again until a white solid precipitates, add 230 mL of dichloromethane for extraction, stir and stand for separation to obtain a dichloromethane phase, and then concentrate the dichloromethane phase to a paste. 10 mL of dichloromethane was added according to the pre-crystallization liquid concentration of 22:100 g / mL, and n-hexane was added dropwise until a solid was precipitated. The mixture was filtered and dried to obtain 2.1 g of a finished product that met the USP quality standard (known impurities avermectin B1a = 0%, 8a-oxo-H2B1a = 0.07%, the sum of H4B1a isomers and Δ2,3H2B1a = 0%; unknown single impurity = 0.45%. Ivermectin main peak chromatographic purity = 98.49%;), with a total yield of 57%.

[0030] Example 3

[0031] The fermentation liquid obtained by fermentation of ivermectin-producing strains is separated into filter residues by a plate-and-frame filter device, and then ethanol extract is obtained by leaching with acetone; 1.8L of acetone extract containing ivermectin (containing 4.14g of ivermectin) is taken and loaded onto an SP-207 resin column. After loading, water washing is started, and then eluted with a 90% acetone-water (V:V) solution. The obtained eluate begins to be concentrated until there is no droplet, 1.5L of chloroform is added for extraction, and after stirring and standing for separation, a chloroform phase is obtained, and the chloroform phase is concentrated to a paste, and 80mL of acetonitrile is added to dissolve to prepare the column liquid, and the liquid phase detection concentration is 41.4mg / mL. The above-mentioned dissolved liquid is loaded into a DAC50 preparative liquid chromatograph with nano-micro C18 filler, and the mobile phase is 88% acetonitrile-water solution, the ultraviolet detection wavelength is 254nm, and the flow rate is 60mL / min. Collect the effective components, and then combine them to control the known impurities avermectin B1a ≤ 0.7%, 8a-oxo-H2B1a ≤ 1%, the sum of H4B1a isomers and Δ2,3H2B1a ≤ 2.5%; unknown single impurities ≤ 0.5%, and the chromatographic purity of the main peak of ivermectin ≥ 98%; re-concentrate the qualified components until a white solid precipitates, add 260 mL of ethyl acetate for extraction, stir and stand for separation to obtain an ethyl acetate phase, and then concentrate the ethyl acetate phase to a paste. 30 mL of ethyl acetate was added according to the pre-crystallization liquid concentration of 10:100 g / mL, and n-hexane was added dropwise until a solid was precipitated. The mixture was filtered and dried to obtain 2.1 g of a finished product that met the USP quality standard (known impurities avermectin B1a = 0%, 8a-oxo-H2B1a = 0.26%, the sum of H4B1a isomers and Δ2,3H2B1a = 0%; unknown single impurity = 0.45%. Ivermectin main peak chromatographic purity = 98.81%;), with a total yield of 51%.

[0032] Example 4

[0033] The fermentation liquid obtained by fermenting the ivermectin-producing strain is separated into a filter residue by a plate-and-frame filter device, and then ethanol is used for extraction to obtain an ethanol extract; 2.6L of ethanol extract containing ivermectin (containing 9.6 grams of ivermectin) is taken and loaded onto an LX-60 resin column. After loading, water washing is started, and then eluted with an 85% ethanol-water (V:V) solution. The obtained eluate begins to be concentrated until there is no droplet, 3.5L of hexane is added for extraction, and after stirring and standing for liquid separation, a hexane phase is obtained, and the hexane phase is concentrated to a paste, and 200mL of methanol is added to dissolve to prepare a column liquid, and the liquid phase detection concentration is 38.5mg / mL. The above-mentioned dissolved liquid is loaded into a DAC50 preparative liquid chromatograph with Kromasil C18 filler, and the mobile phase is 75% methanol aqueous solution, the ultraviolet detection wavelength is 254nm, and the flow rate is 70mL / min. Collect the effective components, and then combine them to control the known impurities avermectin B1a ≤ 0.7%, 8a-oxo-H2B1a ≤ 1%, the sum of H4B1a isomers and Δ2,3H2B1a ≤ 2.5%; unknown single impurities ≤ 0.5%, and the chromatographic purity of the main peak of ivermectin ≥ 98%; re-concentrate the qualified components until a white solid precipitates, add 600 mL of dichloromethane for extraction, stir and stand to separate the liquids, and obtain a dichloromethane phase, and then concentrate the dichloromethane phase to a paste. 31 mL of dichloromethane was added according to the pre-crystallization liquid concentration of 15:100 g / mL, and n-hexane was added dropwise until a solid was precipitated. The mixture was filtered and dried to obtain 4.7 g of a finished product that met the USP quality standard (known impurities avermectin B1a = 0%, 8a-oxo-H2B1a = 0.37%, the sum of H4B1a isomers and Δ2,3H2B1a = 0%; unknown single impurity = 0.56%. Ivermectin main peak chromatographic purity = 9871%;), with a total yield of 49%.

[0034] Example 5

[0035] The fermentation liquid obtained by fermenting the ivermectin-producing strain is separated into a filter residue by a plate-and-frame filter device, and then ethanol is used for extraction to obtain an ethanol extract; 1.3L of ethanol extract containing ivermectin (containing 5.4 grams of ivermectin) is taken and loaded onto an LX-98 resin column. After loading, water washing is started, and then eluted with a 75% ethanol-water (V:V) solution. The obtained eluate begins to be concentrated until there is no droplet, 1.9L of ethyl acetate is added for extraction, and after stirring and standing for separation, an ethyl acetate phase is obtained, and the ethyl acetate phase is then concentrated to a paste, and 110mL of methanol is added to dissolve to obtain a preparative column liquid, and the liquid phase detection concentration is 39.1mg / mL. The above-mentioned dissolved liquid is loaded into a DAC50 preparative liquid chromatograph with Kromasil C18 filler, and the mobile phase is 90% methanol aqueous solution, the ultraviolet detection wavelength is 254nm, and the flow rate is 50mL / min. Collect the effective components, and then combine them to control the known impurities avermectin B1a ≤ 0.7%, 8a-oxo-H2B1a ≤ 1%, the sum of H4B1a isomers and Δ2,3H2B1a ≤ 2.5%; unknown single impurities ≤ 0.5%, and the chromatographic purity of the main peak of ivermectin ≥ 98%; re-concentrate the qualified components until a white solid precipitates, add 340 mL of ethyl acetate for extraction, stir and stand for separation to obtain an ethyl acetate phase, and then concentrate the ethyl acetate phase to a paste. 10 mL of ethyl acetate was added according to the pre-crystallization liquid concentration of 30:100 g / mL, and n-hexane was added dropwise until a solid was precipitated. The mixture was filtered and dried to obtain 2.9 g of a finished product that met the USP quality standard (known impurities avermectin B1a = 0%, 8a-oxo-H2B1a = 0.51%, the sum of H4B1a isomers and Δ2,3H2B1a = 0%; unknown single impurity = 0.49%. Ivermectin main peak chromatographic purity = 98.55%;), with a total yield of 53%.

[0036] Example 6

[0037] The fermentation liquid obtained by fermenting the ivermectin-producing strain is separated into a filter residue by a plate-and-frame filter device, and then ethanol is used for extraction to obtain an ethanol extract; 28L of ethanol extract containing ivermectin (containing 72.8 grams of ivermectin) is taken and loaded onto an LX-30 resin column. After loading, water washing is started, and then eluted with an 85% ethanol-water (V:V) solution. The obtained eluate begins to be concentrated until there is no droplet, 26L of ethyl acetate is added for extraction, and after stirring and standing for separation, an ethyl acetate phase is obtained, and the ethyl acetate phase is then concentrated to a paste, and 1.5L of methanol is added to dissolve to obtain a preparative column liquid, and the liquid phase detection concentration is 38.8mg / mL. The above-mentioned dissolved liquid is loaded into a DAC50 preparative liquid chromatograph with Kromasil C18 filler, and the mobile phase is 83% methanol aqueous solution, the ultraviolet detection wavelength is 254nm, and the flow rate is 70mL / min. Collect the effective components, and then combine them to control the known impurities avermectin B1a ≤ 0.7%, 8a-oxo-H2B1a ≤ 1%, the sum of H4B1a isomers and Δ2,3H2B1a ≤ 2.5%; unknown single impurities ≤ 0.5%, and the chromatographic purity of the main peak of ivermectin ≥ 98%; re-concentrate the qualified components until a white solid precipitates, add 4.5L of ethyl acetate for extraction, stir and stand to separate the liquids, and obtain the ethyl acetate phase, and then concentrate the ethyl acetate phase to a paste, according to 25: 100g / mL of pre-crystallization liquid concentration was added with ethyl acetate 180mL, and then n-hexane was added dropwise until solids were precipitated, and then filtered and dried to obtain 44.4 grams of finished products that met USP quality standards (known impurities avermectin B1a = 0%, 8a-oxo-H2B1a = 0.31%, the sum of H4B1a isomers and Δ2,3H2B1a = 0%; unknown single impurity = 0.37%. Ivermectin main peak chromatographic purity = 98.80%;), with a total yield of 61%.

[0038] Example 7

[0039] The fermentation liquid obtained by fermenting the ivermectin-producing strain is separated into a filter residue by a plate-and-frame filter device, and then ethanol is used for extraction to obtain an ethanol extract; 31L of ethanol extract containing ivermectin (containing 68.2 grams of ivermectin) is taken and loaded onto an LX-30 resin column. After loading, water washing is started, and then eluted with a 70% ethanol-water (V:V) solution. The obtained eluate begins to be concentrated until there is no droplet, 24L of ethyl acetate is added for extraction, and after stirring and standing for separation, an ethyl acetate phase is obtained, and the ethyl acetate phase is then concentrated to a paste, and 1.3L of methanol is added to dissolve to obtain a preparative column liquid, and the liquid phase detection concentration is 41.9mg / mL. The above-mentioned dissolved liquid is loaded into a DAC50 preparative liquid chromatograph with Kromasil C18 filler, and the preparative mobile phase is a 70% methanol aqueous solution, the ultraviolet detection wavelength is 254nm, and the flow rate is 70mL / min. Collect the effective components, and then combine them to control the known impurities avermectin B1a ≤ 0.7%, 8a-oxo-H2B1a ≤ 1%, the sum of H4B1a isomers and Δ2,3H2B1a ≤ 2.5%; unknown single impurities ≤ 0.5%, and the chromatographic purity of the main peak of ivermectin ≥ 98%; re-concentrate the qualified components until a white solid precipitates, add 4.2L of ethyl acetate for extraction, stir and stand to separate the liquids, and obtain the ethyl acetate phase, and then concentrate the ethyl acetate phase to a paste, according to 30: 100 mL of ethyl acetate was added to the pre-crystallization liquid with a concentration of 100 g / mL, and n-hexane was added dropwise until a solid was precipitated. The product was filtered and dried to obtain 37.5 g of a finished product that met the USP quality standard (known impurities avermectin B1a = 0%, 8a-oxo-H2B1a = 0.28%, the sum of H4B1a isomers and Δ2,3H2B1a = 0%; unknown single impurity = 0.42%. Ivermectin main peak chromatographic purity = 98.79%;), with a total yield of 55%.

Claims

1. A method for purifying ivermectin, The following steps are involved: a) separating the ivermectin fermentation liquid from solid, extracting the slag with an organic solvent I, loading the extract onto a macroporous adsorption resin, eluting with an organic solvent I-water solution, collecting and concentrating the eluate I, adding an extractant I to the concentrate for extraction, and concentrating the extracted organic phase to a paste to obtain a paste I; b) dissolving the paste I obtained in step a) with an organic solvent II to prepare a column liquid, and feeding the obtained column liquid into a preparative liquid chromatography column, using an organic solvent II-aqueous solution as a mobile phase, performing chromatographic detection, and collecting an ivermectin qualified component eluate II; c) concentrating the eluate II obtained in step b) until a white solid precipitates, adding an extractant II for extraction, concentrating the extracted organic phase to a paste to obtain a paste II, adding an organic solvent III for dissolution, adding n-hexane dropwise to the obtained pre-crystallization liquid to precipitate crystals, filtering and drying to obtain the finished ivermectin; The macroporous adsorption resin in step a) is selected from polystyrene resin; the preparative filler of the preparative liquid chromatography column in step b) is C18 filler; the organic solvent III in step c) is selected from ethyl acetate and dichloromethane; the organic solvent II in step b) is selected from methanol or acetonitrile; the extractant I and the extractant II in steps a) and c) are selected from chloroform, dichloromethane, ethyl acetate, hexane; the organic solvent I in step a) is selected from ethanol, acetone, and methanol.

2. The method for purifying ivermectin according to claim 1, It is characterized in that The polystyrene resin in step a) is selected from LX-T28, LX-30, LX-60, LX-T83, LX-98, PAD900, and SP-207.

3. The method for purifying ivermectin according to any one of claims 1 to 2, It is characterized in that In the step b), the C18 filler is selected from Nano-C18 filler, Huapu C18 filler, and Kromasil C18 filler.

4. The method for purifying ivermectin as claimed in claim 3, It is characterized in that In the step c), the mass volume ratio of the paste to the organic solvent III is 10-30:100 g / mL.

5. The method for purifying ivermectin as claimed in claim 4, It is characterized in that In the step c), the mass volume ratio of the paste to the organic solvent III is 25:100 g / mL.

6. The method for purifying ivermectin according to claim 5, It is characterized in that In the step b), the mass volume ratio of the paste to the organic solvent II is 2-5:100 g / mL.

7. The method for purifying ivermectin according to claim 6, It is characterized in that In the step b), the ratio of organic solvent II to water in the mobile phase is 80% to 90%; and the flow rate is 50 mL / min to 70 mL / min.

8. The method for purifying ivermectin according to claim 7, It is characterized in that In the step b), the ratio of organic solvent II to water in the mobile phase is 85%; and the flow rate is 70 ml / min.

9. The method for purifying ivermectin according to claim 8, It is characterized in that In the steps a) and c), the mass volume ratio of the paste I to the extractant I is 0.6-0.8:100 g / mL, and the mass volume ratio of the paste II to the extractant II is 1.2-1.6:100 g / mL.

10. The method for purifying ivermectin according to claim 1 or 2, It is characterized in that The macroporous adsorption resin has a particle size of 0.35 mm to 0.45 mm, a pore size of 150 Å, and a spherical shape.

11. The method for purifying ivermectin according to claim 10, It is characterized in that In the step a), the volume ratio of the organic solvent I to the aqueous solution is 70% to 90%.

12. The method for purifying ivermectin according to claim 3, It is characterized in that The particle size of the preparative filler of the preparative liquid chromatography column is 8 μm and the pore size is 100 Å.

Citation Information

Patent Citations

  • Strain of Streptomyces for producing antiparasitic compounds

    US4429042A

  • Purification process for anti-parasitic fermentation product

    US6265571B1

  • Method for isolating and purifying tenvermectin

    CN110540556A

  • Process for the whole broth extraction of avermectin

    US4423211A